Sebela Pharmaceuticals, Inc.
http://www.sebelapharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sebela Pharmaceuticals, Inc.
Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow
Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.
Lilly Looks To Take POINT On Emerging Cancer Radiopharmaceutical Space
Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a strong position in an emerging field.
Lilly Looks To Complement Mounjaro, Obesity Pipeline With Versanis Buyout
Deal brings Lilly a Phase II activin receptor-targeting antibody that could provide another tool in battling obesity. This is Lilly’s fourth M&A transaction since 20 June.
Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Braintree Laboratories Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice